Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.37 |
| ▸ | NPY1R | P25929 | 3/20 | 0.37 |
| ▸ | NPY4R | P50391 | 3/20 | 0.37 |
| ▸ | NPY2R | P49146 | 1/20 | 0.37 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.36 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.35 |
| ▸ | FURIN | P09958 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17722946 | 1.00 | FAP (0.45) | FAPNPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL21912925 | 1.00 | FAP (0.45) | FAPNPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL22643670 | 1.00 | FAP (0.45) | FAPNPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL17815311 | 1.00 | FAP (0.45) | FAPNPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL21861811 | 1.00 | FAP (0.45) | FAPNPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL20935053 | 0.95 | FAP (0.45) | FAPNPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL22314405 | 0.95 | FAP (0.45) | FAPNPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL21998545 | 0.95 | FAP (0.45) | FAPNPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL23877006 | 0.94 | FAP (0.44) | FAPNPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL20841072 | 0.93 | FAP (0.44) | FAPNPY5RNPY1RNPY4RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4104865-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| EP-3229844-B1 | ANTIBODY DRUG CONJUGATES WITH CELL PERMEABLE BCL-XL INHIBITORS | ABBVIE INC (US) | 2020-03-04 | — | — | EP | disclosed |
| WO-2017214335-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2017-12-14 | — | — | WO | disclosed |